Gromeier, Matthias http://orcid.org/0000-0003-4538-0302
Brown, Michael C. http://orcid.org/0000-0002-3957-1164
Zhang, Gao http://orcid.org/0000-0001-8617-8886
Lin, Xiang
Chen, Yeqing
Wei, Zhi http://orcid.org/0000-0001-6059-4267
Beaubier, Nike http://orcid.org/0000-0002-5956-0198
Yan, Hai
He, Yiping
Desjardins, Annick
Herndon, James E. II
Varn, Frederick S. http://orcid.org/0000-0001-6307-016X
Verhaak, Roel G. http://orcid.org/0000-0003-2773-0436
Zhao, Junfei
Bolognesi, Dani P.
Friedman, Allan H.
Friedman, Henry S.
McSherry, Frances
Muscat, Andrea M.
Lipp, Eric S. http://orcid.org/0000-0002-4372-5533
Nair, Smita K. http://orcid.org/0000-0001-7019-1912
Khasraw, Mustafa http://orcid.org/0000-0003-3249-9849
Peters, Katherine B.
Randazzo, Dina
Sampson, John H. http://orcid.org/0000-0002-0104-7658
McLendon, Roger E. http://orcid.org/0000-0001-6682-4588
Bigner, Darell D.
Ashley, David M.
Article History
Received: 21 August 2020
Accepted: 30 November 2020
First Online: 13 January 2021
Competing interests
: M.G., M.C.B., A.D., D.P.B., H.S.F., S.K.N., J.H.S., D.D.B., and D.M.A. own intellectual property related to PVSRIPO, which has been licensed to Istari Oncology, Inc. M.G., A.D., D.P.B, A.H.F., H.S.F., and D.D.B. hold equity in Istari Oncology, Inc. M.G., D.P.B., and D.D.B. are paid consultants of Istari Oncology, Inc. A.D. is on the advisory board of Orbus Therapeutics and receives research support from Orbus Therapeutics, Symphogen, Celgene, Bristol-Myers Squibb. H.Y. receives royalties from Genetron, Agios Pharmaceuticals, and Personal Genome Diagnostics (PGDX); he is CSO with owner interest in Genetron Holdings. M.K. receives institutional research funding from AbbVie, Bristol-Myers Squibb, and Specialized Therapeutics, and honoraria for consultancy/advisory roles with AbbVie, Bristol-Myers Squibb, Eli Lilly, Ipsen, Pfizer, and Roche. J.H.S. has an equity interest in Annias Immunotherapeutics, which has licensed intellectual property from Duke related to the use of the pepCMV vaccine in the treatment of GBM. J.H.S. is an inventor on patents related to PEP-CMV DC vaccine with tetanus, as well as PVSRIPO and D2C7 in the treatment of GBM. If the technology is commercially successful in the future, Dr. Sampson (and any other conflicted individuals on the manuscript) and Duke may benefit financially. The remaining authors declare no competing interests.